Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective Targets

Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias

(2019) Ronald A.M. Buijsen et al.   Neurotherapeutics

Effect of endocannabinoid signalling on cell fate: life, death, differentiation and proliferation of brain cells

(2018) Moises Garcia-Arencibia et al.   BRITISH JOURNAL OF PHARMACOLOGY

The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes

(2018) Javier Fernández-Ruiz   BRITISH JOURNAL OF PHARMACOLOGY

Machado-Joseph disease / Spinocerebellar ataxia type 3:lessons from disease pathogenesis and clues into therapy

(2018) Carlos Matos et al.   JOURNAL OF NEUROCHEMISTRY

Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

(2018) Maria S. Aymerich et al.   BIOCHEMICAL PHARMACOLOGY

Polyglutamine spinocerebellar ataxias — from genes to potential treatments

(2017) Henry L. Paulson et al.   NATURE REVIEWS NEUROSCIENCE

Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3

(2017) Carmen Rodríguez-Cueto et al.   PLoS One

Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models

(2017) Lauren R. Moore et al.   Molecular Therapy-Nucleic Acids

Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype

(2016) Mariana Conceição et al.   BIOMATERIALS

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

(2016) Jose Luis López-Sendón Moreno et al.   JOURNAL OF NEUROLOGY

Does modulation of the endocannabinoid system have potential therapeutic utility in cerebellar ataxia?

(2016) G. J. Stephens   JOURNAL OF PHYSIOLOGY-LONDON

Degenerative ataxias, from genes to therapies

(2016) Stefan M. Pulst   NEUROLOGY

Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3

(2016) Carmen Rodríguez-Cueto et al.   NEUROSCIENCE

Safety and efficacy of valproic acid treatment in SCA3/MJD patients

(2016) Li-Fang Lei et al.   PARKINSONISM & RELATED DISORDERS

Cannabinoids to treat spinal cord injury

(2016) Angel Arevalo-Martin et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Endocannabinoid signalling and the deteriorating brain

(2015) Vincenzo Di Marzo et al.   NATURE REVIEWS NEUROSCIENCE

Polyglutamine aggregation in Huntington's disease and spinocerebellar ataxia type 3: similar mechanisms in aggregate formation

(2015) K. Seidel et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications

(2015) Javier Fernández-Ruiz et al.   Neurotherapeutics

Autosomal dominant cerebellar ataxias: a systematic review of clinical features

(2014) M. Rossi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Chronic Treatment with 17-DMAG Improves Balance and Coordination in A New Mouse Model of Machado-Joseph Disease

(2014) Anabela Silva-Fernandes et al.   Neurotherapeutics

Endocannabinoid-Hydrolysing Enzymes in the Post-Mortem Cerebellum of Humans Affected by Hereditary Autosomal Dominant Ataxias

(2014) Carmen Rodríguez-Cueto et al.   PATHOBIOLOGY

Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado–Joseph disease

(2013) Isabel Nascimento-Ferreira et al.   BRAIN

Changes in CB1and CB2receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias

(2013) Carmen Rodríguez-Cueto et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Reciprocal Cerebellar Circuitry in Human Hereditary Ataxia

(2013) Arnulf H. Koeppen et al.   CEREBELLUM

Two Novel Mutations inABHD12: Expansion of the Mutation Spectrum in PHARC and Assessment of Their Functional Effects

(2013) Dong-Hui Chen et al.   HUMAN MUTATION

Thedu2Jmouse model of ataxia and absence epilepsy has deficient cannabinoid CB1receptor-mediated signalling

(2013) Xiaowei Wang et al.   JOURNAL OF PHYSIOLOGY-LONDON

Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data

(2013) Heike Jacobi et al.   LANCET NEUROLOGY

ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC

(2013) Jacqueline L. Blankman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7

(2013) Udo Rüb et al.   PROGRESS IN NEUROBIOLOGY

Brain pathology of spinocerebellar ataxias

(2012) Kay Seidel et al.   ACTA NEUROPATHOLOGICA

Cell biology of spinocerebellar ataxia

(2012) Harry T. Orr   JOURNAL OF CELL BIOLOGY

Mouse Models of Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)

(2012) Veronica F. Colomer Gould   Neurotherapeutics

The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors

(2011) J. R. Savinainen et al.   Acta Physiologica

Update on degenerative ataxias

(2011) Thomas Klockgether   CURRENT OPINION IN NEUROLOGY

Tolerance to cannabinoid-induced behaviors in mice treated chronically with ethanol

(2011) Matthew J. Pava et al.   PSYCHOPHARMACOLOGY

Mutations in ABHD12 Cause the Neurodegenerative Disease PHARC: An Inborn Error of Endocannabinoid Metabolism

(2010) Torunn Fiskerstrand et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Silencing ataxin-3 mitigates degeneration in a rat model of Machado–Joseph disease: no role for wild-type ataxin-3?

(2010) Sandro Alves et al.   HUMAN MOLECULAR GENETICS

Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond

(2010) Alexandra Durr   LANCET NEUROLOGY

HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3

(2010) An-Hsun Chou et al.   NEUROBIOLOGY OF DISEASE

Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3

(2009) Fiona M. Menzies et al.   BRAIN

Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality

(2009) Jeannie Hwang et al.   LIFE SCIENCES

SCA3: Neurological features, pathogenesis and animal models

(2008) Olaf Riess et al.   CEREBELLUM